Prehypertension and the Cardiometabolic Syndrome

  • Talma RosenthalEmail author
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)


Approaches to DASH eating plan and increased engagement in physical activity have shown to effectively lower BP and thus are recommended as the first choice for prehypertension management.

Individuals with BP in the upper range of prehypertension (130–139/85–89 mmHg) have a significantly higher risk for cardiovascular disease (CVD).

Pharmacological antihypertensive treatment, specifically trials assessing renin-angiotensin system blockers, has also demonstrated good efficacy and safety.

Numerous studies have shown the relative risk of progression to incident hypertension can be reduced by 20% with intensive lifestyle interventions and by 34–66% with single antihypertensive drug treatment.

More recent research has focused on early detection of additional risk factors among them serum C3 and serum uric acid that may serve as biomarkers in high-risk individuals to improve primary prevention of prehypertension and prediabetes.


Complement C3 Serum uric acid Trophy study Attica study Impaired t-PA 


  1. 1.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003;289(19):2560–71.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Mancia G. Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.PubMedGoogle Scholar
  3. 3.
    Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study. Lancet. 2001;358(9294):1682–6.PubMedGoogle Scholar
  4. 4.
    Shen L, Ma H, Xiang M-X, Wang J-A. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol. 2013;112(2):266–71.PubMedGoogle Scholar
  5. 5.
    Vasan RS, Larson MG, Leip EP, Evans JC, O’donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001;345(18):1291–7.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang S, Wu H, Zhang Q, Xu J, Fan Y. Impact of baseline prehypertension on cardiovascular events and all-cause mortality in the general population: a meta-analysis of prospective cohort studies. Int J Cardiol. 2013;168(5):4857–60.PubMedGoogle Scholar
  7. 7.
    McInnes G. Pre-hypertension: how low to go and do drugs have a role? Br J Clin Pharmacol. 2012;73(2):187–93.PubMedPubMedCentralGoogle Scholar
  8. 8.
    De Marco M, De Simone G, Roman MJ, Chinali M, Lee ET, Russell M, et al. Cardiovascular and metabolic predictors of progression of prehypertension into hypertension. Hypertension. 2009;54(5):974–80.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Chobanian AV. Prehypertension revisited. Hypertension. 2006;48:812–4.PubMedGoogle Scholar
  10. 10.
    Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157(6):657–67.Google Scholar
  11. 11.
    Lien LF, Brown AJ, Ard JD, Loria C, Erlinger TP, Feldstein AC, et al. Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension. 2007;50(4):609–16.PubMedGoogle Scholar
  12. 12.
    Crist LA, Champagne CM, Corsino L, Lien LF, Zhang G, Young DR. Influence of change in aerobic fitness and weight on prevalence of metabolic syndrome. Prev Chronic Dis. 2012;9:E68.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Faselis C, Doumas M, Kokkinos JP, Panagiotakos D, Kheirbek R, Sheriff HM, et al. Exercise capacity and progression from prehypertension to hypertension novelty and significance. Hypertension. 2012;60(2):333–8.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Beck DT, Martin JS, Casey DP, Braith RW. Exercise training improves endothelial function in resistance arteries of young prehypertensives. J Hum Hypertens. 2014;28(5):303–9.PubMedGoogle Scholar
  15. 15.
    Beck DT, Martin JS, Casey DP, Braith RW. Exercise training reduces peripheral arterial stiffness and myocardial oxygen demand in young prehypertensive subjects. Am J Hypertens. 2013;26(9):1093–102.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Egan BM, Stevens-Fabry S. Prehypertension—prevalence, health risks, and management strategies. Nat Rev Cardiol. 2015;12(5):289–300.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BMW. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208–19.PubMedGoogle Scholar
  18. 18.
    Segura J, Ruilope LM. Treatment of prehypertension in diabetes and metabolic syndrome. Diabetes Care. 2009;32(Suppl 2):S284–9.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure—a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26(7):1487–96.PubMedGoogle Scholar
  20. 20.
    Julius S, Nesbitt S, Egan B, Kaciroti N, Schork MA, Grozinski M, et al. Trial of preventing hypertension. Hypertension. 2004;44(2):146–51.PubMedGoogle Scholar
  21. 21.
    Julius S, Kaciroti N, Egan BM, Nesbitt S, Michelson EL, Trial of Preventing Hypertension (TROPHY) Investigators. TROPHY study: outcomes based on the seventh report of the joint National Committee on hypertension definition of hypertension. J Am Soc Hypertens. 2008;2(1):39–43.PubMedGoogle Scholar
  22. 22.
    Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, et al. An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the trial of preventing hypertension (TROPHY). J Clin Hypertens. 2008;10(6):436–42.Google Scholar
  23. 23.
    Yao W, Sun Y, Wang X, Si Q, Chen H, Wan Z. High prevalence of metabolic syndrome in a middle-aged and elderly population with prehypertension in Tianjin. Clin Exp Hypertens. 2015;37(5):369–74.PubMedGoogle Scholar
  24. 24.
    Okada R, Yasuda Y, Tsushita K, Wakai K, Hamajima N, Matsuo S. The number of metabolic syndrome components is a good risk indicator for both early-and late-stage kidney damage. Nutr Metab Cardiovasc Dis. 2014;24(3):277–85.PubMedGoogle Scholar
  25. 25.
    Cordero A, Laclaustra M, León M, Grima A, Casasnovas JA, Luengo E, et al. Prehypertension is associated with insulin resistance state and not with an initial renal function impairment: a Metabolic Syndrome in Active Subjects in Spain (MESYAS) Registry substudy. Am J Hypertens. 2006;19(2):189–96.PubMedGoogle Scholar
  26. 26.
    Hwu C-M, Liou T-L, Hsiao L-C, Lin M-W. Prehypertension is associated with insulin resistance. QJM. 2009;102(10):705–11.PubMedGoogle Scholar
  27. 27.
    Sathiyapriya V, Nandeesha H, Bobby Z, Pavithran P, Selvaraj N, Rattina DN. Insulin resistance and enhanced protein glycation in men with prehypertension. Clin Chem Lab Med. 2006;44(12):1457–61.PubMedGoogle Scholar
  28. 28.
    Natali A, Muscelli E, Casolaro A, Nilsson P, Melander O, Lalic N, et al. Metabolic characteristics of prehypertension: role of classification criteria and gender. J Hypertens. 2009;27(12):2394–402.PubMedGoogle Scholar
  29. 29.
    Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJP. Cardiovascular metabolic syndrome--an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab. 2007;9(3):218–32.PubMedGoogle Scholar
  30. 30.
    Duprez D, Toleuova A. Prehypertension and the cardiometabolic syndrome: pathological and clinical consequences. Expert Rev Cardiovasc Ther. 2013;11(12):1725–33.PubMedGoogle Scholar
  31. 31.
    Zhang Y, Lee ET, Devereux RB, Yeh J, Best LG, Fabsitz RR, et al. Prehypertension, diabetes, and cardiovascular disease risk in a population-based sample. Hypertension. 2006;47(3):410–4.PubMedGoogle Scholar
  32. 32.
    Kim NH, Cho HJ, Kim YJ, Cho MJ, Choi HY, Eun CR, et al. Combined effect of high-normal blood pressure and low HDL cholesterol on mortality in an elderly Korean population: the South-West Seoul (SWS) study. Am J Hypertens. 2011;24(8):918.PubMedGoogle Scholar
  33. 33.
    Pletcher MJ, Bibbins-Domingo K, Lewis CE, Wei GS, Sidney S, Carr JJ, et al. Prehypertension during young adulthood and coronary calcium later in life. Ann Intern Med. 2008;149(2):91–9.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Diehl KJ, Weil BR, Greiner JJ, Wright KP, Stauffer BL, DeSouza CA. Impaired endogenous fibrinolytic capacity in prehypertensive men. J Hum Hypertens. 2015;29(8):468–72.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Hrafnkelsdóttir T, Wall U, Jern C, Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet. 1998;352(9140):1597–8.PubMedGoogle Scholar
  36. 36.
    Van Guilder GP. It is time to contend with the endothelial consequences of prehypertension. J Hum Hypertens. 2015;29(8):457.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Patil SG, Aithala M, Das KK. Evaluation of arterial stiffness in elderly with prehypertension. Indian J Physiol Pharmacol. 2015;59(1):16–22.Google Scholar
  38. 38.
    Tomiyama H, Yamashina A. Arterial stiffness in prehypertension: a possible vicious cycle. J Cardiovasc Transl Res. 2012;5(3):280–6.PubMedGoogle Scholar
  39. 39.
    Celik T, Yuksel UC, Fici F, Celik M, Yaman H, Kilic S, et al. Vascular inflammation and aortic stiffness relate to early left ventricular diastolic dysfunction in prehypertension. Blood Press. 2013;22(2):94–100.PubMedGoogle Scholar
  40. 40.
    Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens. 2004;17(7):568–73.PubMedGoogle Scholar
  41. 41.
    Julius S, Egan BM, Kaciroti NA, Nesbitt SD, Chen AK, TROPHY Investigators. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension. J Hypertens. 2014;32(2):251–9.PubMedGoogle Scholar
  42. 42.
    Onat A, Can G, Rezvani R, Cianflone K. Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta. 2011;412(13):1171–9.PubMedGoogle Scholar
  43. 43.
    Bao X, Xia Y, Zhang Q, Wu HM, Du HM, Liu L, et al. Elevated serum complement C3 levels are related to the development of prediabetes in an adult population: the Tianjin Chronic Low-Grade Systematic Inflammation and Health Cohort Study. Diabet Med. 2016;33(4):446–53.PubMedGoogle Scholar
  44. 44.
    Bao X, Meng G, Zhang Q, Liu L, Wu H, Du H, et al. Elevated serum complement C3 levels are associated with prehypertension in an adult population. Clin Exp Hypertens. 2017;39(1):42–9.PubMedGoogle Scholar
  45. 45.
    Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int. 2005;67(5):1739–42.PubMedGoogle Scholar
  46. 46.
    Saladini F, Mos L, Fania C, Garavelli G, Casiglia E, Palatini P. Regular physical activity prevents development of hypertension in young people with hyperuricemia. J Hypertens. 2017;35(5):994–1001.PubMedGoogle Scholar
  47. 47.
    Lotufo PA, Baena CP, Santos IS, Bensenor IM. Serum uric acid and prehypertension among adults free of cardiovascular diseases and diabetes: baseline of the Brazilian longitudinal study of adult health (ELSA-Brasil). Angiology. 2016;67(2):180–6.PubMedGoogle Scholar
  48. 48.
    Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007;25(8):1583–9.PubMedGoogle Scholar
  49. 49.
    Jiang M, Gong D, Fan Y. Serum uric acid levels and risk of prehypertension: a meta-analysis. Clin Chem Lab Med. 2017;55(3):314–21.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Physiology and PharmacologyTel-Aviv University, Sackler School of MedicineTel AvivIsrael

Personalised recommendations